Structure-activity studies of phenanthroindolizidine alkaloids as potential antitumor agents

被引:74
作者
Gao, Wenli
Bussom, Scott
Grill, Susan P.
Gullen, Elizabeth A.
Hu, You-Cai
Huang, Xueshi
Zhong, Sanbao
Kaczmarek, Conrad
Gutierrez, Julio
Francis, Samson
Baker, David C.
Yu, Shishan
Cheng, Yung-Chi
机构
[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA
[2] Chinese Acad Med Sci, Inst Mat Med, Beijing 100050, Peoples R China
[3] Peking Union Med Coll, Beijing 100050, Peoples R China
[4] Univ Tennessee, Dept Chem, Knoxville, TN 37996 USA
关键词
phenanthroindolizidine alkaloids; structure-activity relationships; antitumor activity;
D O I
10.1016/j.bmcl.2007.05.021
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Five phenanthroindolizidine alkaloids (PA) were chemically synthesized and seven were isolated from Tylophora atrofolliculata. To facilitate future drug design of phenanthroindolizidine alkaloids as potential antitumor agents, we have explored the structure-activity relationships (SAR) of this class of compounds. We demonstrated that DCB-3503 and tylophorinidine (PA-7) were among the most active compounds against tumor growth both in vitro and in vivo. In the hepatocellular carcinoma cell line HepG2, the GI(50)S of DCB-3503 and PA-7 were 35 +/- 5 nM and 11 +/- 5 nNI, respectively. DCB-3503 and PA-7 significantly inhibited HepG2 tumor growth in nude mice at a dose of 9 mg/kg given by intraperitoneal (ip) injections twice a day every third day for a total of four cycles (P < 0.05 for DCB-3503 and P < 0.01 for PA-7). Their potent antitumor activities correlated with their potent NF-kappa B-inhibitory effects and their cyclin D1 down-regulatory effects. (c) 2007 Elsevier Ltd. All rights reserved.
引用
收藏
页码:4338 / 4342
页数:5
相关论文
共 24 条
[1]   Nuclear factor-kappa B and cancer: its role in prevention and therapy [J].
Bharti, AC ;
Aggarwal, BB .
BIOCHEMICAL PHARMACOLOGY, 2002, 64 (5-6) :883-888
[2]   Overexpression of cyclin D1 promotes tumor cell growth and confers resistance to cisplatin-mediated apoptosis in an elastase-myc transgene-expressing pancreatic tumor cell line [J].
Biliran, H ;
Wang, Y ;
Banerjee, X ;
Xu, HM ;
Heng, H ;
Thakur, A ;
Bollig, A ;
Sarkar, FH ;
Liao, JD .
CLINICAL CANCER RESEARCH, 2005, 11 (16) :6075-6086
[3]   ALPHA-AMINO-ACIDS AS CHIRAL EDUCTS FOR ASYMMETRIC PRODUCTS - CHIRALLY SPECIFIC SYNTHESES OF TYLOPHORINE AND CRYPTOPLEURINE [J].
BUCKLEY, TF ;
RAPOPORT, H .
JOURNAL OF ORGANIC CHEMISTRY, 1983, 48 (23) :4222-4232
[4]   Overexpression of cyclin D1 and c-Myc gene products in human primary epithelial ovarian cancer [J].
Chen, CH ;
Shen, J ;
Lee, WJ ;
Chow, SN .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :878-883
[5]   Abrogation of skin disease in lupus-prone MRL/Faslpr mice by means of a novel tylophorine analog [J].
Choi, Jin-Young ;
Gao, Wenli ;
Odegard, Jared ;
Shiah, Her-Shyong ;
Kashgarian, Michael ;
McNiff, Jennifer M. ;
Baker, David C. ;
Cheng, Yung-Chi ;
Craft, Joseph .
ARTHRITIS AND RHEUMATISM, 2006, 54 (10) :3277-3283
[6]   Expedient synthesis and structure-activity relationships of phenanthroindolizidine and phenanthroquinolizidine alkaloids [J].
Chuang, TH ;
Lee, SJ ;
Yang, CW ;
Wu, PL .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2006, 4 (05) :860-867
[7]   INHIBITION OF PROTEIN SYNTHESIS IN EHRLICH ASCITES-TUMOUR CELLS BY PHENANTHRENE ALKALOIDS [J].
DONALDSO.GR ;
ATKINSON, MR ;
MURRAY, AW .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1968, 31 (01) :104-&
[8]   Minireview: Cyclin D1: Normal and abnormal functions [J].
Fu, MF ;
Wang, CG ;
Li, ZP ;
Sakamaki, T ;
Pestell, RG .
ENDOCRINOLOGY, 2004, 145 (12) :5439-5447
[9]   Synthesis and structure-activity studies of antofine analogues as potential anticancer agents [J].
Fu, Ye ;
Lee, Sang Kook ;
Min, Hye-Young ;
Lee, Taeho ;
Lee, Jaekwang ;
Cheng, Maosheng ;
Kim, Sanghee .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (01) :97-100
[10]   Novel mode of action of tylophorine analogs as antitumor compounds [J].
Gao, WL ;
Lam, W ;
Zhong, SB ;
Kaczmarek, C ;
Baker, DC ;
Cheng, YC .
CANCER RESEARCH, 2004, 64 (02) :678-688